Breaking News Instant updates and real-time market news.

VRX

Valeant

$13.45

-0.02 (-0.15%)

12:32
05/19/17
05/19
12:32
05/19/17
12:32

Wells says generic Apriso competition may come much sooner than Valeant expected

After the U.S. Patent Office's Trials and Appeal Board ruled that patents related to Valeant's Apriso were unpatentable, Wells Fargo analyst David Maris said the decision may allow generic competition to the ulcerative colitis drug a "dozen years" earlier than Valeant anticipated. Valeant's 2016 10-K does not list Apriso as one of products the company sees facing generic competition between 2017 and 2021, noted Maris, who adds that it is possible that Valeant appeals the PTAB decision. Maris keeps an Underperform rating on Valeant shares.

  • 22

    May

  • 06

    Jun

  • 24

    Aug

VRX Valeant
$13.45

-0.02 (-0.15%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.

TODAY'S FREE FLY STORIES

ALNY

Alnylam

$64.09

-1.71 (-2.60%)

07:34
05/31/17
05/31
07:34
05/31/17
07:34
Hot Stocks
FDA grants Breakthrough Therapy Designation for Alnylam's Givosiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

DAKT

Daktronics

$9.28

0.14 (1.53%)

07:33
05/31/17
05/31
07:33
05/31/17
07:33
Earnings
Daktronics reports Q4 EPS 2c, consensus 6c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

EC

Ecopetrol

$9.36

-0.23 (-2.40%)

07:33
05/31/17
05/31
07:33
05/31/17
07:33
Downgrade
Ecopetrol rating change  »

Ecopetrol downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNKN

Dunkin' Brands

$58.32

0.15 (0.26%)

07:32
05/31/17
05/31
07:32
05/31/17
07:32
Hot Stocks
Dunkin' Brands names Kate Jaspon as CFO, effective June 5 »

Dunkin' Brands Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EXAS

Exact Sciences

$32.65

-0.67 (-2.01%)

, UNH

UnitedHealth

$176.59

-0.91 (-0.51%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Recommendations
Exact Sciences, UnitedHealth analyst commentary  »

Exact Sciences remains a…

EXAS

Exact Sciences

$32.65

-0.67 (-2.01%)

UNH

UnitedHealth

$176.59

-0.91 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 06

    Jun

QCOM

Qualcomm

$57.34

-0.18 (-0.31%)

, NXPI

NXP Semiconductors

$108.14

0.14 (0.13%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Hot Stocks
Qualcomm extends cash tender offer for NXP Semiconductors outstanding shares »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$57.34

-0.18 (-0.31%)

NXPI

NXP Semiconductors

$108.14

0.14 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 09

    Jun

FRO

Frontline

$5.41

-0.22 (-3.91%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Upgrade
Frontline rating change  »

Frontline upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGHT

8x8, Inc.

$13.60

0.1 (0.74%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Conference/Events
8x8, Inc. management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 01

    Jun

  • 06

    Jun

  • 06

    Jun

  • 08

    Jun

  • 13

    Jun

GNRT

Gener8 Maritime

$4.91

0.06 (1.24%)

, FRO

Frontline

$5.41

-0.22 (-3.91%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Recommendations
Gener8 Maritime, Frontline, DHT Holdings analyst commentary  »

Gener8 Maritime advance…

GNRT

Gener8 Maritime

$4.91

0.06 (1.24%)

FRO

Frontline

$5.41

-0.22 (-3.91%)

DHT

DHT Holdings

$4.20

-0.07 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$7.28

-0.69 (-8.66%)

, ORCL

Oracle

$45.42

0.16 (0.35%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

WLL

Whiting Petroleum

$7.28

-0.69 (-8.66%)

ORCL

Oracle

$45.42

0.16 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:25
05/31/17
05/31
07:25
05/31/17
07:25
Technical Analysis
Technical View: Michael Kors drops to new 52-week low after earnings »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CBS

CBS

$61.52

-0.05 (-0.08%)

, CBS.A

$63.50

-0.15 (-0.24%)

07:24
05/31/17
05/31
07:24
05/31/17
07:24
Periodicals
Scott Pelley to depart anchor role on 'CBS Evening News,' NY Times says »

CBS (CBS, CBS.A) news…

CBS

CBS

$61.52

-0.05 (-0.08%)

CBS.A

$63.50

-0.15 (-0.24%)

CMCSA

Comcast

$41.10

0.19 (0.46%)

CMCSK

Comcast

DIS

Disney

$108.34

-0.07 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 08

    Jun

  • 15

    Jun

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:23
05/31/17
05/31
07:23
05/31/17
07:23
Hot Stocks
Breaking Hot Stocks news story on Michael Kors »

Michael Kors drops 7% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

UAA

Under Armour

$19.56

-0.13 (-0.66%)

07:23
05/31/17
05/31
07:23
05/31/17
07:23
Recommendations
Under Armour analyst commentary  »

Under Armour has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

07:22
05/31/17
05/31
07:22
05/31/17
07:22
General news
Futures higher ahead of final trading for May »

Stock futures are above…

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:22
05/31/17
05/31
07:22
05/31/17
07:22
Hot Stocks
Michael Kors says to close 100-125 full-price retail stores over next two years »

Michael Kors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MYL

Mylan

$39.36

-0.36 (-0.91%)

07:19
05/31/17
05/31
07:19
05/31/17
07:19
Recommendations
Mylan analyst commentary  »

Pension fund campaign a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Oct

VIAB

Viacom

$35.05

-0.08 (-0.23%)

, VIA

Viacom

$38.90

0.5 (1.30%)

07:17
05/31/17
05/31
07:17
05/31/17
07:17
Recommendations
Viacom, Viacom analyst commentary  »

Viacom price target…

VIAB

Viacom

$35.05

-0.08 (-0.23%)

VIA

Viacom

$38.90

0.5 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$1.37

-0.02 (-1.44%)

07:17
05/31/17
05/31
07:17
05/31/17
07:17
Hot Stocks
22nd Century reports 'dramatic surge' in VLN tobacco clinical trials, science »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$45.00

0.29 (0.65%)

07:16
05/31/17
05/31
07:16
05/31/17
07:16
Recommendations
Abbott analyst commentary  »

Abbott making progress, …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$52.11

-0.29 (-0.55%)

07:15
05/31/17
05/31
07:15
05/31/17
07:15
Hot Stocks
Garmin launches Approach S60 golf watch »

Garmin International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$36.45

-0.76 (-2.04%)

07:15
05/31/17
05/31
07:15
05/31/17
07:15
Technical Analysis
Technical View: U.S. Silica trades higher in pre-market »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

GPRK

GeoPark

$8.71

-0.18 (-2.02%)

07:12
05/31/17
05/31
07:12
05/31/17
07:12
Hot Stocks
GeoPark names Coulter Enterprises Chairman and CEO Coulter to board »

GeoPark Limited announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRQR

ProQR Therapeutics

$4.70

-0.3 (-6.00%)

07:12
05/31/17
05/31
07:12
05/31/17
07:12
Hot Stocks
ProQR Therapeutics' QR-110 granted Fast Track designation by FDA »

ProQR Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$66.30

-0.57 (-0.85%)

07:11
05/31/17
05/31
07:11
05/31/17
07:11
Downgrade
Molina Healthcare rating change  »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.